[ad_1]
July 31 (Reuters) – Mammoth Biosciences said on Tuesday it was $ 23 million in funding for the development of a biotech platform based on CRISPR technology
CRISPR works as a type
[Abstract] [Abstract] [Abstract] [AbstractavailableinEnglishDescriptionavailableinEnglishClaims(1)availableinGermanNonfiction19659002] The funds from the series A fundraising round-robin will help the San-Francisco-based company build its infrastructure and intellectual property portfolio, Mammoth said
The round was led by venture capital firm Mayfield with participation from NFX and 8VC. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)
[ad_2]
Source link
